Table: Treatments Considered for COVID-19 (Archived) (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

April 6, 2020

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the role of available and investigational drugs in the management of COVID-19.

Select a term to see related articles ACE inhibitors acetaminophen Actemra Advil anakinra Angiotensin receptor blockers antiretrovirals ARBs Atazanavir Avigan azithromycin baricitinib Chloroquine cobicistat Coronavirus corticosteroids COVID-19 darunavir favipravir HIV Hydroxychloroquine ibuprofen influenza ivermectin Jakafi Kaletra Kevzara Kineret Lopinavir melatonin Motrin NSAIDs Olumiant oseltamivir Plaquenil Prezcobix remdesivir Reyataz ribavirin Ritonavir ruxolitinib sarilumab Stromectol tocilizumab Tylenol vaccines Zinc Zithromax

Archived; last update: April 1, 2022

View the Table: Treatments Considered for COVID-19

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.